期刊文献+

微血管侵犯对肝细胞癌肝移植术后预后的影响 被引量:3

Effect of the microvascular invasion on the prognosis of hepatocellular carcinoma after liver transplantation
下载PDF
导出
摘要 目的:探讨微血管侵犯(microvascular invasion,MVI)对肝细胞癌(HCC)肝移植术后预后的影响。方法:回顾性分析HCC行原位肝移植手术病人183例的临床和随访资料,其中符合米兰标准76例,USCF标准84例,上海标准102例,杭州标准126例。用Kaplan-Meier法计算4组1年、3年、5年累积生存率,并用Log-Rank检验比较各组生存曲线的差异。将每组分为MVI和无MVI亚组,比较肿瘤复发率、5年无瘤生存率及1年、3年、5年生存率。结果:4组病人的生存时间差异均无统计学意义(P>0.05);随着HCC肝移植标准扩大,MVI率逐渐升高(P<0.05),3年、5年生存率和5年无瘤生存率均逐渐降低(P<0.05)。符合上海标准病人中,无MVI亚组肿瘤复发率低于MVI亚组(P<0.05),5年生存率和5年无瘤生存率均高于MVI亚组(P<0.05);符合杭州标准病人中,无MVI亚组肿瘤复发率低于MVI亚组(P<0.05),3年、5年生存率和5年无瘤生存率均高于MVI亚组(P<0.05~P<0.01)。结论:MVI可预测符合上海标准和杭州标准的HCC肝移植术后复发情况,对肝移植综合治疗具有指导意义。 Objective:To investigate the ettects of microvascular invasion(MVI) on the prognosis of hepatocellular carcinoma ( HCC ) alter liver transplantation. Methods:The clinical data of 183 HCC patients treated with orthotopic liver transplantation were retrospec-tively analyzed. Sevenly-six cases according with the Milan standard,84 cases according with USCF standard, 102 cases according with Shanghai standard and 126 cases according with Hangzhou standard were identified. The 1-year, 3-year and 5-year cumulative survival rates in four groups were calculated using Kaplan-Meier method,and the ditterences of survival curves among the four groups were com- pared using Log-Rank test. Each group was subdivided into the MVI group and non-MVI group, and the recurrence rate of tumor,5-year disease-free survival rate, and l-year, 3-year,5-year survival rates were compared between two groups. Results:There was no statistical significance in survival time among four groups (P 〉 0.05 ). With the expansion of liver transplantation standard, the MVI rate gradually increased, the 3-year, 5-year survival rates and 5-year disease-free survival rate gradually decreased( P 〈 0.05 ). Among the patients ac-cording with Shanghai standard, the tumor recurrence rate in non -MVI group was lower than that in MVI group (P 〈 0.05 ) , and the 5-year survival rate and 5-year disease-free survival rate in non-MVI group were higher than that in non-MVI group( P 〈 0.05 ). Among the patients according with Hangzhou standard,the tumor recurrence rate in non-MVI group was lower than that in MVI group(P 〈 0. 05 ) , and the 5-year survival rate and 5-year disease-free survival rate in MVI group were higher than that in MVI group (P 〈 0.05 to P 〈 0.01 ). Conehlsions : Microvascular invasion can predict the recurrence of HCC after liver transplantation, which has guiding signifi-cance in comprehensive treatment of liver transplantation.
作者 刘建勇 杨芳 蔡秋程 翁亮 黄兴华 江艺 LIU Jian-yong;YANG Fang;CAI Qui-cheng;WENG Liang;HUA Xing-hua;JIANG Yi(Department of Hepatobiliary Surgery,Fuzhou General Hospital,Fuzhou Fujian 350025,China)
出处 《蚌埠医学院学报》 CAS 2018年第10期1364-1367,共4页 Journal of Bengbu Medical College
基金 福建省自然科学基金面上项目(2016J01585)
关键词 肝肿瘤 微血管侵犯 肝移植 生存率 liver neoplasms microvascular invasion liver transplantation survival rate
  • 相关文献

参考文献6

二级参考文献49

  • 1樊嘉,周俭,徐泱,邱双健,吴志全,余耀,黄晓武,汤钊猷,王玉琦.肝癌肝移植适应证的选择:上海复旦标准[J].中华医学杂志,2006,86(18):1227-1231. 被引量:121
  • 2杨广顺,尤天庚,田利国.原发性肝癌肝移植治疗———我们的共识[J].中国实用外科杂志,2006,26(7):481-482. 被引量:10
  • 3吴孟超.应重视小肝癌的诊断与治疗[J].中华医学杂志,2007,87(30):2089-2091. 被引量:11
  • 4Burra P, Germani G, Adam R, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes.J Hepatol , 2013, 58(2) :287-296.
  • 5Yu L, Dai Z, Wang Z, et al. Prognostic indicators for tumor recurrence after liver transplantation in hepatocellular carcinoma and related molecular targeted therapy. Oncology, 2011, 81 Suppl L, 116-122.
  • 6Fan], YangGS, Fu ZR, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi?center experience in Shanghai, China.J Cancer Res Clin Oncol , 2009, 135(10): 1403-1412.
  • 7Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N EnglJ Med, 1996. 334(11):693-699.
  • 8Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology, 2001,33(6): 1394-1403.
  • 9MarshJW, Dvorchik I, Bonham CA. et al, Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer, 2000, 88(3) :538-543.
  • 10Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer] cu?. 2011, 61(2) :69-90.

共引文献169

同被引文献19

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部